Leerink Partnrs Issues Negative Outlook for Cencora Earnings

Cencora, Inc. (NYSE:COR) – Research analysts at Leerink Partnrs lowered their Q4 2025 earnings estimates for shares of Cencora in a report released on Monday, October 6th. Leerink Partnrs analyst M. Cherny now forecasts that the company will post earnings per share of $3.80 for the quarter, down from their prior estimate of $3.81. The consensus estimate for Cencora’s current full-year earnings is $15.37 per share. Leerink Partnrs also issued estimates for Cencora’s Q1 2026 earnings at $4.09 EPS, Q2 2026 earnings at $4.98 EPS, Q3 2026 earnings at $4.34 EPS, Q4 2026 earnings at $4.17 EPS, FY2027 earnings at $19.43 EPS, FY2028 earnings at $21.36 EPS and FY2029 earnings at $23.60 EPS.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, beating analysts’ consensus estimates of $3.79 by $0.21. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business had revenue of $80.66 billion for the quarter, compared to the consensus estimate of $80.34 billion. During the same quarter last year, the firm posted $3.34 EPS. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year.

A number of other brokerages also recently commented on COR. Wells Fargo & Company raised their target price on shares of Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a research note on Wednesday, August 13th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Cencora in a research note on Saturday, September 27th. Morgan Stanley set a $330.00 price target on shares of Cencora and gave the stock an “equal weight” rating in a research note on Wednesday, July 16th. Finally, Jefferies Financial Group lifted their price target on shares of Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research note on Monday, June 30th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and a consensus price target of $314.55.

Cencora Stock Performance

Shares of COR stock opened at $305.32 on Tuesday. The company’s fifty day simple moving average is $295.07 and its 200-day simple moving average is $290.68. Cencora has a 52 week low of $218.65 and a 52 week high of $315.23. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. The company has a market cap of $59.20 billion, a PE ratio of 31.41, a P/E/G ratio of 1.41 and a beta of 0.63.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were given a $0.55 dividend. The ex-dividend date of this dividend was Friday, August 15th. This represents a $2.20 annualized dividend and a dividend yield of 0.7%. Cencora’s payout ratio is presently 22.63%.

Insider Activity

In other news, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction dated Thursday, September 18th. The stock was sold at an average price of $290.00, for a total transaction of $1,478,130.00. Following the completion of the sale, the chief executive officer directly owned 39,274 shares of the company’s stock, valued at $11,389,460. The trade was a 11.49% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 55,993 shares of company stock valued at $16,292,923 in the last three months. Insiders own 10.80% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Atlantic Edge Private Wealth Management LLC increased its stake in Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after buying an additional 35 shares during the period. Net Worth Advisory Group increased its stake in Cencora by 1.4% in the 1st quarter. Net Worth Advisory Group now owns 2,645 shares of the company’s stock valued at $736,000 after buying an additional 36 shares during the period. Obermeyer Wealth Partners increased its stake in Cencora by 1.3% in the 1st quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company’s stock valued at $758,000 after buying an additional 36 shares during the period. Grove Bank & Trust increased its stake in shares of Cencora by 4.3% during the 2nd quarter. Grove Bank & Trust now owns 879 shares of the company’s stock worth $264,000 after purchasing an additional 36 shares during the last quarter. Finally, Quadcap Wealth Management LLC raised its holdings in shares of Cencora by 1.5% during the 2nd quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock valued at $722,000 after purchasing an additional 36 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.